
|Articles|October 1, 2010
Dermatology Times, Digital Edition, October 2010
EHRs, Worth the Hassle? : ‘Meaningful use’ criteria can pose high hurdle for derms Allergan Settles : Drugmaker to pay $600 million to resolve off-label marketing charges Special Report : Hair & Nails
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Clears IND Application of Recludix’s Oral STAT6, REX-8756
2
The Aesthetic Edge: December 2025
3
Phase 3 Data Position Zasocitinib as a Potential New Oral Option for Psoriasis
4
Dermatologic Effects of Energy and High Protein Drinks
5

















